The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Benzodiazepines compromise the outcome of cancer immunotherapy
Open accessAbstract
) acts on the gamma-amino butyric acid (GABA) receptor type A via a specific binding site that is shared by diazepam and other benzodiazepines. Both ACBP/DBI and benzodiazepines act as positive allosteric modulators, hence increasing GABA effects on this receptor. Recently, we found that ACBP/DBI acts as an endogenous immunosuppressor, meaning that its antibody-mediated neutralization has immunostimulatory effects and enhances the efficacy of immunotherapy and chemoimmunotherapy in mouse models. Driven by these considerations, we investigated whether diazepam administration in mice would reverse the beneficial effects of ACBP/DBI neutralization on cancer chemoimmunotherapy. Indeed, diazepam abolished the therapeutic of anti-ACBP/DBI antibodies, supporting the idea that diazepam exerts immunosuppressive properties. Of note, treatment with benzodiazepines was associated with poor clinical responses to chemoimmunotherapy in patients with non-small cell lung cancer (NSCLC) as compared to individuals not receiving any psychotropic drugs. Medication with other psychotropic drugs than benzodiazepines did not compromise the outcome of chemoimmunotherapy, indicating that this immunosuppressive effect was benzodiazepine specific. We conclude that benzodiazepines may confer systemic immunosuppression. This hypothesis requires further epidemiological and clinical confirmation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Benzodiazepine has also been shown to compromise immunotherapy, with preclinical and clinical data demonstrating that these agents suppress anti-tumor immune responses and correlate with reduced survival in NSCLC patients receiving programmed death protein-1 (PD-1) blockade.90,106”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [106]
Experimental — accuracy not yet measuredIn the citing paper
“Pending further confirmation in large clinical studies, such guidelines might be extended to recommend healthy diets and to warn against the use of proton pump inhibitors 95 , benzodiazepines 96 and over-the-counter probiotics 97 , which are all associated with poor immunotherapy outcome.”
From Impact of the ONCOBIOME network in cancer microbiome research (2025) · cites this paper as [96]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Simple Practice Guide for Dose Conversion between Animals and Human
Nair, A., & Jacob, S. (2016) · Journal of Basic and Clinical Pharmacy · doi:10.4103/0976-0105.177703 · Cited by 6,174 · cited 1×
“27 The custom-made ACBP/DBI-neutralizing monoclonal antibody 1,8 or the corresponding isotype control (mouse IgG2a, BioXCell, #BE0085) was diluted in PBS and injected i.p. at 5 mg/kg. Oxaliplatin (Sigma, #Y0000271) was dissolved to a concentration of 1 mg/mL in ddH 2 O, sterile-filtered and…”
MethodGlobal Burden of Disease 2019 Cancer Collaboration, Kocarnik, J. M., Compton, K., Dean, F. E., Fu, W., Gaw, B. L., Harvey, J. D., Henrikson, H. J., Lu, D., Pennini, A., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2021.6987 · Cited by 2,026
Immune checkpoint therapy—current perspectives and future directions
Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S. K., Poon, C., Gant, K. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.006 · Cited by 1,206
Benzodiazepines: use, abuse, and consequences.
Woods, J. H., Katz, J. L., & Winger, G. (1992) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00468-5 · Cited by 560
Caloric restriction mimetics enhance anticancer immunosurveillance
Pietrocola, F., Pol, J., Vacchelli, E., Rao, S., Enot, D. P., Baracco, E. E., Levesque, S., Castoldi, F., Jacquelot, N., Yamazaki, T., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.016 · Cited by 542
Self-citationRudolph, U., & Möhler, H. (2004) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121429 · Cited by 519 · cited 1×
“43,44 ,45,46 Of note, some benzodiazepines such as olanzapine induce weight gain as a major side effect, 47,48 suggesting (but not proving) that they act on GABA A R outside of the CNS.”
BackgroundActivating autophagy to potentiate immunogenic chemotherapy and radiation therapy
Galluzzi, L., Bravo-San Pedro, J. M., Demaria, S., Formenti, S. C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.183 · Cited by 314
Self-citationMontégut, L., López-Otín, C., & Kroemer, G. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02020-z · Cited by 190 · cited 1×
“…determinant of the success of anticancer treatments, 2,3 (ii) that aging and obesity are the most important risk factors of neo-plastic diseases, 4,5 that (iii) ACBP/DBI is a tissue hormone that increases with age and overweight/obesity, 6,7 and (iv) that circulating ACBP/DBI is particularly…”
BackgroundSelf-citationImmunosurveillance in clinical cancer management
Kroemer, G., Chan, T. A.-T., Eggermont, A. M. M., & Galluzzi, L. (2023) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21818 · Cited by 177
Self-citationDecaudin, D., Castedo, M., Némati, F., Beurdeley‐Thomas, A., Pinieux, G. D. B. D., Caron, A., Pouillart, P., Wijdenes, J., Rouillard, D., Kroemer, G., et al. (2002) · PubMed · Cited by 176
Self-citation
Cited by
Pharmacomicrobiomics: The Role of the Gut Microbiome in Immunomodulation and Cancer Therapy
Bolte, L. A., Björk, J. R., Gaćeša, R., & Weersma, R. K. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.04.025 · Cited by 41
Elkrief, A., Routy, B., Derosa, L., Bolte, L. A., Wargo, J. A., McQuade, J. L., & Zitvogel, L. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-472902 · Cited by 43
Self-citationGut dysbiosis in oncology: a risk factor for immunoresistance
(2026) · doi:10.1038/s41422-025-01212-6 · Cited by 24
Self-citationImpact of the ONCOBIOME network in cancer microbiome research
Zitvogel, L., Derosa, L., Routy, B., Loibl, S., Heinzerling, L., de Vries, I. J. M., Engstrand, L., ONCOBIOME Network, Silva, C. A. C., Barbieri, D., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03608-8 · Cited by 23
“Pending further confirmation in large clinical studies, such guidelines might be extended to recommend healthy diets and to warn against the use of proton pump inhibitors 95 , benzodiazepines 96 and over-the-counter probiotics 97 , which are all associated with poor immunotherapy outcome.”
Self-citationZhou, S., Song, X., Zeng, W., & Chen, D. (2025) · Pharmaceuticals · doi:10.3390/ph18101521 · Cited by 17
“Similarly, diazepam use in NSCLC patients correlates with poorer responses to chemoimmunotherapy compared to non-users [282].”
Metadata
- Authors
- Montégut, L., Derosa, L., Messaoudene, M., Chen, H., Lambertucci, F., Routy, B., Zitvogel, L., Martins, I., & Kroemer, G.
- Affiliations
- Institut Gustave Roussy (FR)
- Inserm (FR)
- Centre Hospitalier de l’Université de Montréal (CA)
- Corresponding author
- Martins, Isabelle
- Kroemer, Guido
- ORCID
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2024-10-07
- Volume
- 13
- Issue
- 1
- Pages
- 2413719-2413719
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- PMC
- PMC11459736
- OpenAlex
- W4403190877
- Cited by
- 18
- References
- 51
- Citations by year
- 2026: 8 · 2025: 10
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- OncoImmunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Agence Nationale de la Recherche
- Association pour la Recherche sur le Cancer
- Cancéropôle Ile de France
- Fondation pour la Recherche Médicale
- HORIZON EUROPE European Research Council
- Institut National Du Cancer
- Institut Universitaire de France
- Labex Immuno-Oncology
- Ligue Contre le Cancer
- Hevolution Network on Senescence and Aging
- Elior
- EJPRD
- Mark foundation
- Seerave Foundation
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- benzodiazepines, diazepam, cancer immunotherapy, chemoimmunotherapy, immunosuppression, GABAA receptor, positive allosteric modulators, non-small cell lung cancer, psychotropic drugs
- MeSH terms
- Animals, Benzodiazepines, Diazepam, Humans, Immunotherapy, Lung Neoplasms, Neoplasms, Treatment Outcome, Diazepam Binding Inhibitor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Benzodiazepines compromise the outcome of cancer immunotherapy. https://app.cochat.ai/papers/10.1080/2162402x.2024.2413719
- The paper
- Montégut, L., Derosa, L., Messaoudene, M., Chen, H., Lambertucci, F., Routy, B., Zitvogel, L., Martins, I., & Kroemer, G. (2024). Benzodiazepines compromise the outcome of cancer immunotherapy. OncoImmunology. https://doi.org/10.1080/2162402x.2024.2413719
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.